SK Biopharmaceuticals emerges from pandemic with pitch for $822M IPO
The lively biotech IPO streak isn’t confined in the US — or even Hong Kong for that matter.
On Monday, SK Biopharmaceuticals revealed that it’s eyeing $822 million in what would be the country’s biggest public debut in three years.
Plans for the IPO began as early as last October, when SK filed a preliminary application to the Korean Exchange. Expectations were high, with analysts predicting that it could fetch upwards of 1 trillion won (close to $850 million).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.